Recent Promotions
ENTR1 Knockout HEK293 Cell Line
Cat.No.:
EDJ-KQ7177
Species:
Human
Cell Name:
HEK293
Gene:
ENTR1
Gene ID:
10807
Size:
1×10⁶cells
ENTR1 Knockout Cell Line (HEK293) is an exclusive upgraded CRISPR/Cas9 system-mediated gene knockout cell, with the advantages of Optimized Strategy Design, Efficient Cell Transfection, High-Performance Cas9 Protein and Hassle-Free Cell Selection.
| Cat.No. | EDJ-KQ7177 |
|---|---|
| Product Name | ENTR1 Knockout Cell Line (HEK293) |
| Cell Line | HEK293 |
| Cellosaurus ID | CVCL_0045 |
| Cell Line Synonyms | Hek293, HEK-293, HEK/293, (HEK)293, HEK 293, HEK,293, 293, 293 HEK, 293 Ad5, Graham 293, Graham-293, Human Embryonic Kidney 293 |
| Gene | |
| NCBI Gene ID | |
| Gene Synonyms | NY-CO-3|SDCCAG3|SDDAG3 |
| Summary |
Involved in several processes, including endocytic recycling; positive regulation of cilium assembly; and positive regulation of protein localization to cilium. Located in several cellular components, including endosome; microtubule organizing center; and retromer complex. [provided by Alliance of Genome Resources, Jul 2025]
|
| Associated Diseases | Non-tumor |
| Morphology | Adherent |
| Passage Ratio | 1/5,2days |
| Complete Culture Medium | DMEM + 10% FBS |
| Freezing Medium | 95% Complete culture medium+ 5% DMSO |
| QC | Indels validated by Sanger sequencing; sterility confirmed via microbial testing. |
* For research use only. Not intended for use in humans or animals, including clinical, therapeutic, or diagnostic purposes.
| Loci | STR Info (Sample Cell) Sample Cell Line: HEK293 | STR Info (Cell bank) Cell Line: HEK293 | ||
| Allele1 | Allele2 | Allele1 | Allele2 | |
| Amelogenin | X | X | ||
| CSF1P0 | 12 | 11 | 12 | |
| D2S1338 | 19 | 19 | ||
| D3S1358 | 15 | 17 | 15 | 17 |
| D5S818 | 8 | 8 | 9 | |
| D7S820 | 11 | 12 | 11 | 12 |
| D8S1179 | 12 | 14 | 12 | 14 |
| D13S317 | 12 | 14 | 12 | 14 |
| D16S539 | 9 | 13 | 9 | 13 |
| D18S51 | 17 | 18 | 17 | 18 |
| D19S433 | 15 | 18 | 15 | 18 |
| D21S11 | 28 | 30.2 | 28 | 30.2 |
| FGA | 23 | 23 | ||
| Penta D | 9 | 10 | 9 | 10 |
| Penta E | 7 | 15 | 7 | 15 |
| TH01 | 7 | 9.3 | 7 | 9.3 |
| TPOX | 11 | 11 | ||
| vWA | 16 | 19 | 16 | 19 |
| D6S1043 | 11 | 11 | ||
| D12S391 | 19 | 21 | 11 | 15 |
| D2S441 | 11 | 15 | 11 | 15 |
* STR authentication data of this cell line matches with that of cell lines sourced from ATCC, DSMZ, JCRB, and RIKEN databases.
Conclusion: The STR identification of this cell is correct.
Conclusion: The STR identification of this cell is correct.
* Research Use Disclaimer: Content is generated from publicly available research data, bioinformatic resources, and computational analyses for research reference only.
Research Publications
ENTR1 stabilizes MAVS by inhibiting NIX-mediated mitophagy to restrict BPIV3 and VSV replication.
IF=2.7
Veterinary microbiology
Endosome-associated trafficking regulator 1 (ENTR1) is implicated in cell apoptosis, cytokinesis, and adipogenesis, but its role in antiviral innate immunity has not been elucidated. In this study, we identify ENTR1 as a positive regulatory factor for type I interferon (IFN-I) signaling pathway, which suppresses bovine parainfluenza virus type 3 (BPIV3) and vesicular stomatitis virus (VSV) replication. Further investigations revealed that ENTR1 deficiency enhanced Nip3-like protein X (NIX)-mediated mitophagy, leading to accelerated degradation of mitochondrial antiviral signaling protein (MAVS) during viral infection. Mechanistically, ENTR1 knockout resulted in increased accumulation of NIX on mitochondria, which promoted the autophagic degradation of MAVS. Importantly, silencing NIX rescued MAVS protein levels and significantly reduced viral titers in ENTR1-deficient cells. Moreover, NIX silencing prevented the degradation of MAVS and consequently reduced viral titers in ENTR1-deficient cells. Consequently, our findings reveal a novel regulatory axis in which ENTR1 stabilizes MAVS by suppressing NIX-dependent mitophagy, thereby enhancing antiviral IFN-I responses. This study not only uncovers a previously unrecognized function of ENTR1 in antiviral immunity but also identifies ENTR1 as a potential target for developing broad-spectrum antiviral therapeutics against RNA viruses.
This KO model may be useful for:
- Studying the role of ENTR1 in regulating MAVS stability and antiviral innate immunity.
- Investigating the interplay between mitophagy (NIX-mediated) and viral replication restriction.
- Evaluating host-pathogen interactions, particularly for BPIV3 and VSV infection models.
- Functional validation of ENTR1 as a potential therapeutic target against RNA virus infections.
- Exploring the molecular mechanisms of mitophagy-dependent immune evasion by viruses.